Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study

Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study

Background: After the publication of the ABC-02 trial, gemcitabine and cisplatin combination therapy (GP) became the standard first-line treatment for advanced biliary tract cancer (BTC). Despite GP therapy, most patients suffer from disease progression. The ABC-06 trial recommended FOLFOX as a seco...

Full description

Bibliographic Details
Main Authors: Go, S.-I (Author), Huh, S.J (Author), Ji, J.H (Author), Kang, J.H (Author), Kim, J.H (Author), Kim, K.M (Author), Lee, Y.-P (Author), Oh, S.Y (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
biliary tract cancer
modified FOLFIRINOX
second-line treatment
Online Access:View Fulltext in Publisher

Similar Items

Similar Items